Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical-stage biotechnology company developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Its platform is built around “off-the-shelf” cell therapies engineered with chimeric antigen receptors (CARs), which are intended to be manufactured from unrelated donors and stored for use on demand. The company’s lead program, prulacabtagene autoleucel (prula-cel, formerly ADI-001), is being advanced for autoimmune disease, while ADI-212 is being developed as a next-generation gene-edited and armored candidate for solid tumors. Adicet’s business is still pre-commercial, so its value depends on successful clinical development, regulatory progress, and the ability to scale manufacturing and financing over time.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueInvestigational allogeneic CAR T-cell product candidates being developed for autoimmune disease and oncology.
The underlying donor-derived gamma delta T-cell technology used to create off-the-shelf therapies.
Internal GMP cell processing, vector manufacturing, and supporting CDMO-based supply chain activities.
Historical revenue from the Regeneron collaboration and license agreement.
Customers
Adicet does not yet sell approved products to commercial end customers; its current “customers” are primarily clinical trial participants, investigators, regulators, and collaboration partners. In the near term, the company’s programs are aimed at patients with autoimmune diseases such as lupus nephritis and systemic lupus erythematosus, as well as oncology patients with advanced solid tumors such as metastatic castration-resistant prostate cancer. Revenue to date has come from a collaboration and license agreement with Regeneron, so counterparties in partnering transactions are also economically important. If its programs succeed, future demand would come from hospitals and treatment centers administering specialized cell therapies.
Patients enrolled in prula-cel studies for lupus nephritis and systemic lupus erythematosus, where the therapy is intended to reset B-cell activity after a single dose.
Patients with advanced solid tumors, including metastatic castration-resistant prostate cancer, targeted by ADI-212 in early development.
Biopharma partners that may license programs, share development costs, or provide non-product revenue, as Regeneron has done historically.
Hospitals and research centers that administer the company’s cell therapy trials and generate the clinical data needed for regulatory filings.
Strategy
Adicet’s strategy is to focus capital on a small number of programs with the highest probability of clinical and regulatory value creation. The company has prioritized prula-cel in autoimmune disease and ADI-212 in prostate cancer, while discontinuing ADI-270 and reducing headcount to conserve resources. It aims to submit a new regulatory filing roughly every 12-18 months, which signals a pipeline cadence designed to keep the platform advancing despite limited cash resources. Manufacturing control, supply-chain redundancy, and external CDMO partnerships are central to the strategy because the company needs reliable cell and vector production before commercialization can be contemplated.
This is the lead program and the clearest near-term source of clinical validation for the gamma delta CAR T platform.
ADI-212 expands the platform into oncology and could broaden the company’s value proposition if it shows solid-tumor activity.
As a clinical-stage company with no product revenue, Adicet must manage burn carefully to avoid financing pressure.
Cell therapy development depends on reliable donor material, vector production, and GMP execution.
Geography
Adicet is headquartered in the United States and conducts key manufacturing and development activities at its Redwood City, California facility. The company also formed Adicet Shanghai in 2024 and operates in the PRC through contractual arrangements with a VIE, which creates a China operating footprint without direct equity ownership by public shareholders. Its lead oncology opportunity for ADI-212 is framed around patient prevalence in the U.S., EU5, China, and Japan, indicating a broad future commercial addressable market if development succeeds. Geography matters mainly through regulatory pathways, manufacturing execution, and the legal complexity of operating in China via a VIE structure.
Risks
Adicet faces the classic risks of a clinical-stage biotech company: uncertain trial outcomes, regulatory delays, and the possibility that its product candidates never reach approval. Its dependence on a single collaboration for historical revenue and on external capital for funding makes financing risk especially important, because the company expects to need substantial additional capital. Manufacturing risk is also material because cell therapy programs require consistent donor supply, vector production, and GMP compliance, and any disruption can delay trials or increase costs. The PRC VIE structure adds legal and enforcement risk in China, while broader industry risks include competition from other cell therapy platforms, changing FDA expectations, and the possibility that safety or efficacy data do not translate into commercial success.
- Clinical development failureImpact: CriticalLikelihood: Medium
The company has no approved products, so value depends on prula-cel and ADI-212 proving safe and effective in humans.
Exposure: Lead programs in autoimmune disease and oncology
- Financing riskImpact: HighLikelihood: High
Adicet expects to need substantial additional capital and has limited revenue sources, making dilution or unfavorable financing possible.
Exposure: Operating runway and pipeline execution
- Manufacturing and supply-chain riskImpact: HighLikelihood: Medium
Cell therapy production depends on donor material, viral vectors, and GMP execution, any of which can delay trials or raise costs.
Exposure: Redwood City facility and CDMO network
- PRC legal and VIE structure riskImpact: MediumLikelihood: Medium
The company operates in China through contractual arrangements that may face enforcement or regulatory challenges.
Exposure: Adicet Shanghai and Adicet VIE
- Partner concentration riskImpact: MediumLikelihood: Low
All revenue to date came from the Regeneron collaboration, so termination or non-renewal would remove a key non-dilutive funding source.
Exposure: Collaboration and license revenue
Accounting
Judgemental itemsHistorical revenue came from the Regeneron agreement, so the timing and classification of any collaboration payments can materially affect reported revenue.
Impact: Can create lumpy revenue periods and distort trend analysis
The company estimates costs for outsourced manufacturing and clinical work based on progress and contracted rates, which requires judgment.
Impact: Affects R&D expense and current liabilities
Equity awards are a key part of compensation in a clinical-stage biotech and can materially affect operating loss.
Impact: Affects operating expenses and non-cash burn analysis
The company states it will need additional capital and bases runway estimates on assumptions that may prove wrong.
Impact: Important for assessing financing risk and dilution potential
Similar listed companies
Publicly listed companies with a comparable business focus.
Aditxt, Inc.
ADTX · Pharmaceutical Preparations
Allogene Therapeutics, Inc.
ALLO · Biological Products, (No Diagnostic Substances)
Allogene Therapeutics is a clinical-stage immuno-oncology company developing genetically engineered allogeneic T cell therapies for cancer and autoimmune disease.
Abeona Therapeutics Inc
ABEO · Pharmaceutical Preparations
Jade Biosciences, Inc.
JBIO · Pharmaceutical Preparations
Caribou Biosciences, Inc.
CRBU · Biological Products, (No Diagnostic Substances)
Fate Therapeutics, Inc
FATE · Biological Products, (No Diagnostic Substances)
Fate Therapeutics is a clinical-stage biopharmaceutical company developing off-the-shelf cellular immunotherapies built from human induced pluripotent stem cells (iPSCs).
Last updated: 24/09/2026